A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of elritercept (KER-050) for the treatment of transfusion-dependent anemia in adult participants with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) (RENEW)

MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today